---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033870"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:35:51.798163+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte dosed first patient with LB-100 in new colorectal cancer trial with NKI and Roche support

## Summary
- Dosed first patient in clinical trial NCT06012734 for MSI Low metastatic colorectal cancer.
- Trial collaboration with Netherlands Cancer Institute (NKI); Roche supplies atezolizumab (Tecentriq).
- Second pharma-funded LB-100 immunotherapy trial; earlier GSK trial for clear cell ovarian cancer started 2024.
- Aims to bring immunotherapy to ~85% of colorectal cancer patients currently unresponsive.

## SEC filing metadata
- accession: 0001493152-24-033870
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/0001493152-24-033870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224033870/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033870
- JSON: https://secwatch.observer/filing/0001493152-24-033870.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.